Metsera (MTSR) Q3 2025 earnings summary

Executive summary

• Entered into a definitive merger agreement with Pfizer, valuing equity at ~$10 billion, with $65.60/share in cash plus contingent value rights (CVRs) for milestone achievements; closing expected in Q4 2025, pending regulatory approvals.

• Completed IPO in February 2025, raising $288.4 million in net proceeds; significant capital raised from preferred stock prior to IPO.

• Lead candidate MET-097i showed positive Phase 2b results (14.1% weight loss at 28 weeks) and strong tolerability; Phase 3 initiation planned for late 2025.

Financial highlights

• Net loss of $116.2 million for Q3 2025 and $261.5 million for the nine months ended September 30, 2025, compared to $109.6 million and $156.3 million for the same periods in 2024.

• Research and development expenses increased to $63.7 million for Q3 2025 (up $33.8 million YoY) and $181.4 million for the nine months (up $112.8 million YoY), driven by clinical program ramp-up and personnel costs.

• General and administrative expenses rose to $15.0 million for Q3 2025 (up $7.7 million YoY) and $35.1 million for the nine months (up $18.1 million YoY), mainly due to higher personnel and stock-based compensation.

• Cash and cash equivalents were $448.5 million as of September 30, 2025.

Outlook and guidance

• Existing cash expected to fund operations for at least 12 months from the reporting date.

• Anticipates continued significant operating losses as clinical programs advance and pipeline expands.

• If the merger is not completed, substantial additional capital will be required to fund ongoing operations.